Two new analyses associate improved clinical and economic
outcomes with use of Dario's digital health solution
NEW
YORK, Nov. 21, 2023 /PRNewswire/ -- DarioHealth
Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the
global digital health market, announced today two new analyses
recently presented by Sanofi U.S. demonstrating two mediators
associated with improved clinical and economic in Dario users.
Improved Clinical Outcomes Linked with Improved Medication
Adherence
Presentations by Sanofi U.S. at the Diabetes Technology Society
(DTS) annual conference, held Nov. 2
– 4, examined real-world data from matched Dario users and
non-users with type 2 diabetes to determine the association of
medication adherence from Dario's digital health solution with
blood glucose control.
Dario users saw an overall clinically significant reduction in
HbA1c and an associated 10.6% improvement in medication adherence.
The new research helps explain the results of a previously reported
study on reductions in HbA1c, because medication adherence is
one behavioral component of self-care needed to achieve improved
clinical outcomes.
Improved Economic Outcomes Associated with Digital
Engagement
Sanofi also presented research at ISPOR Europe 2023, held on
November 12-15, 2023, of a new
analysis showing more frequently engaged Dario users were
associated with 10% reduction in all-cause healthcare resource use
over 100 days and were 15% less likely to incur related
charges. Engagement was defined by activities meaningful to
diabetes management, such as taking a blood glucose reading;
inputting an insulin dose; recording physical activity or tagging a
meal.
This new analysis provides additional information from
previously reported study results demonstrating Dario's ability to
contribute to a reduction in all-cause healthcare utilization by 9%
including inpatient hospitalizations by 23% compared to non-users
at 12 months.
"These new analyses help explain how Dario's highly personalized
solutions are able to drive the behavior change underlying the
significant value we've demonstrated in previous research.
Medication adherence is one such behavior we can now point to
alongside engagement in our chronic condition management tools as
mechanisms that work as we intend: driving better outcomes and
lowering costs," said Omar
Manejwala, M.D., Chief Medical Officer of Dario.
"In digital health, specific engagement metrics that relate to
the intended value for a digital therapeutic are referred to as
measures of meaningful engagement. These results showed that
meaningful engagement activities and medication adherence are both
important contributors to the better outcomes in Dario users." said
Felix Lee, Medical Head of Digital
Healthcare at Sanofi U.S.
Dario and Sanofi Research: Setting New Standards for
Evidence-Based Digital Health
These analyses, conducted by Sanofi, are part of Dario and
Sanofi's groundbreaking collaboration to set new standards in
digital health research by analyzing real-world digital health data
using the evidence generation principles of a pharmaceutical study.
To read more about this research, click here.
The analyses used HIPAA-complaint deidentified patient data
linking claims data, electronic medical record data and lab data to
construct the study cohorts. All data in these studies was
collected following receipt of all required patient consents.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health
company revolutionizing how people with chronic conditions manage
their health through a user-centric, multi-chronic condition
digital therapeutics platform. Dario's platform and suite of
solutions deliver personalized and dynamic interventions driven by
data analytics and one-on-one coaching for diabetes, hypertension,
weight management, musculoskeletal pain and behavioral
health.
Dario's user-centric platform offers people continuous and
customized care for their health, disrupting the traditional
episodic approach to healthcare. This approach empowers people to
holistically adapt their lifestyles for sustainable behavior
change, driving exceptional user satisfaction, retention and
results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to
health plans and other payers, self-insured employers, providers of
care and consumers. To learn more about Dario and its digital
health solutions, or for more information, visit
http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it discusses
the potential benefits realized by the use of its products. Without
limiting the generality of the foregoing, words such as "plan,"
"project," "potential," "seek," "may," "will," "expect," "believe,"
"anticipate," "intend," "could," "estimate" or "continue" are
intended to identify forward-looking statements. Readers are
cautioned that certain important factors may affect the Company's
actual results and could cause such results to differ materially
from any forward-looking statements that may be made in this news
release. Factors that may affect the Company's results include, but
are not limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™ as described
herein) may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280
Media Contact:
Scott Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
Logo -
https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/new-research-sheds-light-on-mediators-of-improved-outcomes-in-dario-users-301994728.html
SOURCE DarioHealth Corp.